Cancer is still one of the most widespread life-threatening diseases globally, with nearly all families affected either directly or as caregivers. Innovations in the medical ecosystem continue to gain momentum with the emergence of new immunotherapies, targeted drugs, and advanced radiation treatments. In light of this, LIXTE Biotech (NASDAQ: LIXT) is complementing traditional drug development into the rapidly evolving field of proton therapy, utilizing Liora Technologies, its newly acquired subsidiary (ibn.fm/UihRx).
Towards the end of 2025, the company finalized its acquisition of Liora, signaling its foray into the radiotherapy segment of cancer care. This strategic move includes Liora’s LiGHT system, which stands for Linac for Image Guided Hadron Therapy. This platform is designed to enhance the delivery of proton therapy and address identified limitations in many conventional systems (ibn.fm/mPijd).
Proton therapy is an improved form of radiation therapy that leverages proton particles instead of regular X-rays to destroy tumor DNA. Protons, unlike photon radiation, release most of their energy at a precise depth within the body. This feature helps doctors better target tumors while cutting down radiation exposure to nearby healthy tissue. The precision is crucial when tumors are found close to organs such as the spinal cord, brain, lungs, or heart, and it can be useful for children who are likely to be more susceptible to long-term side effects resulting from radiation (ibn.fm/QqpkB).
Although proton therapy has its own unique clinical benefits, traditional systems are usually complex, large, and expensive. Many such therapies depend on synchrotrons or cyclotrons that require significant resources. These barriers have limited the number of proton therapy centers globally.
Liora’s LiGHT system is currently installed at the Science and Technology Facilities Council Daresbury Laboratory in Britain, with over $300 million invested in it so far. The electronically controlled system enables adaptability, flexibility, and the potential for lower costs of installation compared to the regular alternatives.
The LiGHT system is also created to deliver high dose rates to deep-seated tumors, reducing the number of treatment sessions needed while increasing the total number of patients a treatment center can handle. Improved efficiency could also help improve proton therapy access while also optimizing the financial model for operators.
LIXTE’s acquisition of Liora highlights a strategic expansion that goes beyond its regular pharmaceutical pipeline, with the company’s lead drug candidate, LB 100, currently being assessed in clinical trials for ovarian clear cell carcinoma and metastatic colon cancer. By blending advanced radiation technology and innovative drug development, the company is creating a solid oncology platform that tackles cancer from a broader angle.
Given the growing demand for more effective cancer treatment options, LIXTE’s entry into proton therapy through Liora Technologies and the LiGHT system holds significant potential. Through the blend of next-generation radiation therapy and pharmaceutical innovation, the company is working hard to improve cancer treatment while also creating opportunities for investors.
For more information, visit the company website at https://lixte.com.
NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
A study published this week has found that when cancer cells are stressed, they produce…
For decades, health policymakers have relied on a survey tool to get early awareness of…
BioMedWire Editorial Coverage: Biotechnology mergers and acquisitions (“M&As”) are increasingly shaped by a clear strategic…
In oncology, the biggest constraints are not always science. They are often the logistics, the…
BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies…
A groundbreaking study led by a pair of researchers from Israel and involving research teams…